))
Episode 5: Three Questions with Bob Coughlin from MassBio
Manage episode 337444529 series 3381207
Innehåll tillhandahållet av Gunnar Esiason. Allt poddinnehåll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahålls direkt av Gunnar Esiason eller deras podcastplattformspartner. Om du tror att någon använder ditt upphovsrättsskyddade verk utan din tillåtelse kan du följa processen som beskrivs här https://sv.player.fm/legal.
Gunnar Esiason and Bob Coughlin, the former CEO of MassBio, talk about the state of the biotechnology industry in the background of the COVID-19 pandemic. Bob shares why the biotechnology trade association is important for biotech companies in Massachusetts, before getting into the industry's reputation and how he thinks the pandemic will impact the way people view drug makers. Gunnar talks about why he thinks patients should be able to own clinical trial data, why clinical trials are not accessible enough for diverse patient populations, and how patients should be included throughout the drug development process.
To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy
Learn more about your ad choices. Visit https://podcastchoices.com/adchoices
23 episoder
Dela
